New obesity procedure also reduces muscle mass

Catharine Paddock PhD | November 27, 2018

New obesity procedure also reduces muscle mass
A study about a new procedure for the treatment of obesity has raised some concerns. This is because, while the treatment leads to weight loss, the pounds a person sheds consist of skeletal muscle as well as fat. Also, body fat loss seems to be mainly of the subcutaneous type. Skeletal muscle is necessary for good health; its loss can result in not only physical problems, but it can also impair metabolism and raise the risk of injury. Visceral fat is the type of fat that surrounds the organs deep inside the abdomen. Doctors have linked carrying too much of it to health problems, such as type 2 diabetes and heart disease. The procedure is called left gastric artery embolization. Interventional radiologists have been using it for decades to stop bleeding in emergencies. However, the idea of using gastric artery embolization to treat obesity is new, and clinical trials are currently evaluating its safety and effectiveness for such a purpose. The aim of the treatment is to reduce the effect of an appetite hormone by injecting microscopic beads to block an artery that supplies blood to the stomach. The study's findings featured recently at the annual meeting of the Radiological Society of North America that is currently taking place in Chicago, IL.

Spotlight

There were some 57 million Americans enrolled in Medicare in 2016—with the majority (68 percent) still enrolled in the traditional Medicare fee-for-service program, according to a new infographic by the Centers for Medicare and Medicaid Services. The infographic examines Medicare demographic d


Other News

Intent Data in the Age of Data Regulation

DECK 7 | March 23, 2020

Since the implementation of Data Protection Act in 2018, the approach behind the use of data has changed dramatically. Our clients and customers don’t just want a great experience, they also want to make sure they can trust us. Tweet This! And it makes perfect sense in the present time and space. But as data is considered a key factor in positive customer experience, the U.S. brands and agencies have found it to be increasingly complicated to earn customer trust while remaining compliant. In an article by John Snyder, CEO at Grapeshot, for Adexchanger, he says that the GDPR will remove 75% of third-party data and what’s left will be more expensive. This has caus...

Read More

TScan and Novartis partner to develop cancer therapies

Pharmaceutical Technology | April 16, 2020

Biopharmaceutical firm TScan Therapeutics has signed an agreement with Novartis to discover and develop therapies for the treatment of cancer. The companies aim to work on TCR-engineered T-cell therapies for solid tumours. TScan’s platform will identify cancer antigens that could be targeted by TCR-based treatments. As part of the deal, TScan will find and characterise TCRs while Novartis will hold an option to licence and develop TCRs for up to three new targets. Furthermore, Novartis will have rights of first negotiation for more targets and TCRs resulting from the alliance. TScan may develop TCRs that act on targets not licensed by Novartis. TScan Therapeutics president and CEO Davi...

Read More

BeiGene reports positive Phase III interim analysis for lung cancer drug

MedCity News | April 14, 2020

Interim results from a Phase III clinical trial have shown that patients receiving a cancer immunotherapy drug for a form of lung cancer on top of chemotherapy were more likely than those receiving chemotherapy alone to survive without their disease worsening, the company developing the drug said Monday. Beijing-based BeiGene reported an improvement in progression-free survival (PFS) among first-line patients with non-squamous non-small-cell lung cancer (NSCLC) receiving tislelizumab along with platinum chemotherapy and pemetrexed, compared with those receiving chemotherapy and pemetrexed alone. However, it did not disclose the data. The company said it plans to file for approval of the drug...

Read More

Would-be coronavirus drugs are cheap to make

Science | April 10, 2020

With a vaccine for the novel coronavirus still likely a year or more away, the first weapon against the virus could be one of the drugs now in clinical trials with COVID-19 patients. A new analysis out today shows that many of these drugs, which are currently manufactured or in development to treat other diseases, can be made for $1 a day per patient, or less. If any prove effective against the novel coronavirus, a coordinated international effort will be needed to ensure they are made affordable for people worldwide, the researchers argue. Scientists worldwide are conducting clinical trials on at least a dozen potential treatments for COVID-19. Some compounds have been on the market for dec...

Read More

Spotlight

There were some 57 million Americans enrolled in Medicare in 2016—with the majority (68 percent) still enrolled in the traditional Medicare fee-for-service program, according to a new infographic by the Centers for Medicare and Medicaid Services. The infographic examines Medicare demographic d

Resources

Events